Sandbox Reserved 957: Difference between revisions
No edit summary |
No edit summary |
||
(23 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
<Structure load='2H40' size='350' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' />{{Sandbox_ESBS}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | <Structure load='2H40' size='350' frame='true' align='right' caption='Insert caption here' scene='Insert optional scene name here' />{{Sandbox_ESBS}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> | ||
==Introduction== | ==Introduction== | ||
PDE5, phosphodiesterase 5 (EC 3.1.4.35), is an abundant protein in cell of airway and visceral smooth muscle and vascular cell. It can be found in epithelial cell and in Purkinje cell of the cerebella | PDE5, phosphodiesterase 5 (EC 3.1.4.35), is an abundant protein in cell of airway and visceral smooth muscle and vascular cell. It can be found in epithelial cell and in Purkinje cell of the cerebella <ref>Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA, Corbin JD. Phosphodiesterase-5: molecular characteristics relating to structure, function, and regulation. In: Cyclic Nucleotide Phosphodiesterases in Health and Disease, edited by Beavo JA, Houslay MD, Francis SH. Boca Raton, FL: CRC, 2006, p. 131–164.<br \> | ||
There are 11 families of PDE (from 1 to 9), there is 21 genes for PDE which code 60 different PDE. For the PDE5A, the only PDE5 subcategory, there are 4 isoforms but their catalytic domain is the same | Sekiguchi M, Hoshizaki H, Adachi H, Ohshima S, Taniguchi K, Kurabayashi M. Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. Circ J 68: 610–614, 2004. | ||
Sopory S, Kaur T, Visweswariah SS. The cGMP-binding, cGMPspecific phosphodiesterase (PDE5): intestinal cell expression, regulation and role in fluid secretion. Cell Signal 16: 681–692, 2004.<br \> | |||
Zhu B, Strada S, Stevens T. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 289: L196–L206, 2005.<br \></ref> and platelets and Corpus Cavernosum. In particular, it is implied in the NO pathway of penile erection and so in the Erectile Dysfunction (ED) <ref>JD Corbin, Mechanisms of action of PDE5 inhibition in erectile dysfunction, International Journal of Impotence Research (2004) 16, S4–S7</ref>.<br \> | |||
There are 11 families of PDE (from 1 to 9), there is 21 genes for PDE which code 60 different PDE. For the PDE5A, the only PDE5 subcategory, there are 4 isoforms but their catalytic domain is the same <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref>.<br \> | |||
The catalytic reaction is the hydrolysis of guanosine cyclic monophosphate into linear guanosine monophosphate. This cGMP-specific enzyme have 3 domains (from N terminal to C terminal) : GAF A, GAF B and a conserved catalytic domain regard to other PDEs of the family. Only cGMP can bind GAF A or GAF B and it stimulates the hydrolysis.<br \> | The catalytic reaction is the hydrolysis of guanosine cyclic monophosphate into linear guanosine monophosphate. This cGMP-specific enzyme have 3 domains (from N terminal to C terminal) : GAF A, GAF B and a conserved catalytic domain regard to other PDEs of the family. Only cGMP can bind GAF A or GAF B and it stimulates the hydrolysis.<br \> | ||
We study here the PDE5A catalytic fragment formed of amino acid residues from the 535th to the 860th | We study here the PDE5A catalytic fragment formed of amino acid residues from the 535th to the 860th <ref>http://www.rcsb.org/pdb/explore.do?structureId=2H40</ref>. In the inhibition, we talk about the Sildenafil mostly, because it's the most known (active ingredient in the Viagra®).<br \> | ||
Problem in the PBD files: N-loop (from the 788th to the 881th residues) is not complete. | |||
== Structure of catalytic site == | == Structure of catalytic site == | ||
The only catalytic fragment is effective, so the regulations sites and the dimerization to a trimeric enzyme are useless for the catalytic activity. Moreover, this catalytic moiety has the same activity that the wild-type enzyme, so maybe the enzyme is monomeric in the cell | The only catalytic fragment is effective, so the regulations sites and the dimerization to a trimeric enzyme are useless for the catalytic activity. Moreover, this catalytic moiety has the same activity that the wild-type enzyme, so maybe the enzyme is monomeric in the cell <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref>. | ||
Catalytic domain is conserved for the PDE family, between 20% and 40%, and the variant reactions of the PDE inhibitors on the different PDEs may be caused by the more variant regulatory sites | Catalytic domain is conserved for the PDE family, between 20% and 40%, and the variant reactions of the PDE inhibitors on the different PDEs may be caused by the more variant regulatory sites <ref>Tamara L. Fink, Sharron H. Francis, Alfreda Beasley, Kennard A. Grimes, and Jackie D. Corbin, Expression of an Active, Monomeric Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5), The Journal Of Biological Chemistry, Vol. 274, No. 49, Issue of December 3, pp. 34613–34620, 1999.</ref>.<br \> | ||
The catalytic domain has 3 helical subdomains | The catalytic domain has 3 helical subdomains <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref>:<br \> | ||
* A N-terminal cyclin-fold region with eight helixes | * A N-terminal cyclin-fold region with eight helixes <ref>Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclinA–CDK2 complex. Nature 376, 313–320 (1995).<br \> | ||
Nikolov, D. B. et al. Crystal structure of a TFIIB-TBP-TATA-element ternary complex. Nature 377, 119–128 (1995).</ref>: 5 α-helixes (1, 3, 5, 6 and 8) and 3 3ind10-helixes (2,4, and 7),<scene name='60/604476/537_678/3'> from the 537th to the 678th residues</scene>.<br \> | |||
* A linker domain: two antiparallels α9 and α10 helixes, and between a disordered region,<scene name='60/604476/679-725/2'>from the 679th to the 725th residues</scene>.<br \> | * A linker domain: two antiparallels α9 and α10 helixes, and between a disordered region,<scene name='60/604476/679-725/2'>from the 679th to the 725th residues</scene>.<br \> | ||
* A C-terminal buddle pocket with eight helixes: 5 long α-helixes (11, 12, 14, 17 and 18) and 3 smaller helixes (13, 15 and 16),<scene name='60/604476/726-860/2'> from the 726th to the 860th residues</scene>.<br \> | * A C-terminal buddle pocket with eight helixes: 5 long α-helixes (11, 12, 14, 17 and 18) and 3 smaller helixes (13, 15 and 16),<scene name='60/604476/726-860/2'> from the 726th to the 860th residues</scene>.<br \> | ||
** α5, 6 and 8 surround α3 and form an interface with the linker domain and the CTD.<br \> | ** α5, 6 and 8 surround α3 and form an interface with the linker domain and the CTD.<br \> | ||
The catalytic site is a pocket which is 330Å in volume and a deep of 10Å, with a narrow entry. There are 4 regions: M (with 2 metallic ions), H (hydrophobic), Q (for the substrate), L (the lid or “H-Loop” on both N-term and linker domain). M site is surrounded by the helixes α6, 8, 9, 10 and 12. A majority of aliphatic or hydrophobic residues, that creates the hydrophobic pocket | The catalytic site is a pocket which is 330Å in volume and a deep of 10Å, with a narrow entry. There are 4 regions: M (with 2 metallic ions), H (hydrophobic), Q (for the substrate), L (the lid or “H-Loop” on both N-term and linker domain). M site is surrounded by the helixes α6, 8, 9, 10 and 12. A majority of aliphatic or hydrophobic residues, that creates the hydrophobic pocket <ref>Zoraghi R, Francis SH, Corbin JD. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cGMP and inhibitors. Biochemistry 46: 13554–13563, 2007.</ref>.<br \> | ||
M site contains:<br \> | M site contains:<br \> | ||
* The Me-1 and Me-2 sites are occupied by metal ions, Zinc within Me-1 and within Me-2, Zinc, Magnesium or Manganese | * The Me-1 and Me-2 sites are occupied by metal ions, Zinc within Me-1 and within Me-2, Zinc, Magnesium or Manganese <ref>Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, Menniti FS. Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci USA 105: 13309–13314, 2008.</ref>,<br \> | ||
* The residues <scene name='60/604476/His617_asp654_asp764_his653/1'>His617, Asp654, Asp764, His653</scene> and two H2O (W1 et W2) binding zinc:<br \> | * The residues <scene name='60/604476/His617_asp654_asp764_his653/1'>His617, Asp654, Asp764, His653</scene> and two H2O (W1 et W2) binding zinc:<br \> | ||
** The crucial <scene name='60/604476/Asp764/1'>Asp764</scene> | ** The crucial <scene name='60/604476/Asp764/1'>Asp764</scene> <ref>Turko IV, Francis SH, Corbin JD. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMPspecific phosphodiesterase. J Biol Chem 273: 6460–6466, 1998.</ref> and the conserved His617 and 653<ref>Francis SH, Turko IV, Grimes KA, Corbin JD. Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5. Biochemistry 39: 9591–9596, 2000.</ref>, which bind one Zinc ion, are fundamental for the catalytic activity.<br \> | ||
** <scene name='60/604476/Zn/1'>Zinc</scene> is critical for catalytic activity, but it isn't implied in the formation of the hydrophobic pocket. In fact, even if <scene name='60/604476/His653_his617/1'>the His617and 653</scene> are lost and so the Zn not bound, a massive addition of Manganese | ** <scene name='60/604476/Zn/1'>Zinc</scene> is critical for catalytic activity, but it isn't implied in the formation of the hydrophobic pocket. In fact, even if <scene name='60/604476/His653_his617/1'>the His617and 653</scene> are lost and so the Zn not bound, a massive addition of Manganese<ref>Francis SH, Turko IV, Grimes KA, Corbin JD. Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5. Biochemistry 39: 9591–9596, 2000.</ref> in the medium allows a reactivation of catalysis.<br \> | ||
* W2 binds <scene name='60/604476/Mg_zn/1'>Zn and Mg</scene> | * W2 binds <scene name='60/604476/Mg_zn/1'>Zn and Mg</scene> <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref>,<br \> | ||
* And there are 3 hydrogen bonds between 3 H2O and the conserved resides <scene name='60/604476/His657glu682his685/1'>His657, Asp682 and His685</scene> | * And there are 3 hydrogen bonds between 3 H2O and the conserved resides <scene name='60/604476/His657glu682his685/1'>His657, Asp682 and His685</scene> <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref>.<br \> | ||
Q site contains:<br \> | Q site contains:<br \> | ||
* In particular the conserved residues <scene name='60/604476/Qsite1/1'>Gln817, Phe820, Val782 and Tyr612. | * In particular the conserved residues <scene name='60/604476/Qsite1/1'>Gln817, Phe820, Val782 and Tyr612. <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref></scene><br \> | ||
* The hydrogen bonds, between <scene name='60/604476/Qsite2/1'>Gln817 and 775, Gln775 and Ala767, Gln775 and Trp853</scene>, imply an interaction between <scene name='60/604476/Gln817/1'>Gln817</scene> and the cGMP purine. Thus, it improves the specificity for the cGMP, against cAMP. | * The hydrogen bonds, between <scene name='60/604476/Qsite2/1'>Gln817 and 775, Gln775 and Ala767, Gln775 and Trp853</scene>, imply an interaction between <scene name='60/604476/Gln817/1'>Gln817</scene> and the cGMP purine. Thus, it improves the specificity for the cGMP, against cAMP. <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref><br \> | ||
* And <scene name='60/604476/Qsite3/1'>Tyr612, Val782, Leu785 an Phe820</scene> bind the cGMP through this pyrazol ring and π-π interactions between Gln817 and the phenyl ring. | * And <scene name='60/604476/Qsite3/1'>Tyr612, Val782, Leu785 an Phe820</scene> bind the cGMP through this pyrazol ring and π-π interactions between Gln817 and the phenyl ring. <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref><br \> | ||
** So, the conserved hydrophobic residue <scene name='60/604476/Tyr612/1'>Tyr 612</scene> is critical in the maintaining of the affinity. | ** So, the conserved hydrophobic residue <scene name='60/604476/Tyr612/1'>Tyr 612</scene> is critical in the maintaining of the affinity. <ref>Turko IV, Francis SH, Corbin JD. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMPspecific phosphodiesterase. J Biol Chem 273: 6460–6466, 1998.</ref><br \> | ||
H site:<br \> | H site:<br \> | ||
* In particular the residues <scene name='60/604476/Hsite1/1'>Phe786, Ala783, Leu804, Val782</scene>. | * In particular the residues <scene name='60/604476/Hsite1/1'>Phe786, Ala783, Leu804, Val782</scene>. <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref><br \> | ||
L site:<br \> | L site:<br \> | ||
* In particular the hydrophobic residues <scene name='60/604476/Lsite1/1'>Tyr664, Met816, Ala823, Gly819</scene>. | * In particular the hydrophobic residues <scene name='60/604476/Lsite1/1'>Tyr664, Met816, Ala823, Gly819</scene>. <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref><br \> | ||
Besides, the kcat of the catalytic fragment decreases 40-fold and 8-fold if the residues <scene name='60/604476/Lys603_leu644/1'>His603 and Asp644</scene> are mutated, and so there are important in the catalytic activity | Besides, the kcat of the catalytic fragment decreases 40-fold and 8-fold if the residues <scene name='60/604476/Lys603_leu644/1'>His603 and Asp644</scene> are mutated, and so there are important in the catalytic activity <ref>Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, Menniti FS. Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci USA 105: 13309–13314, 2008.Turko IV, Francis SH, Corbin JD. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMPspecific phosphodiesterase. J Biol Chem 273: 6460–6466, 1998.</ref>. Two others residues are significant: <scene name='60/604476/Gln778/1'>the Gln778</scene> which is important for cGMP affinity but have no impact on cAMP affinity H-loop <ref>Zoraghi R, Corbin JD, Francis SH. Phosphodiesterase-5 Gln817 is critical for cGMP, vardenafil, or sildenafil affinity: its orientation impacts cGMP but not cAMP affinity. J Biol Chem 281: 5553–5558, 2006.</ref> and the conserved <scene name='60/604476/Gly659/1'>Gly659</scene> which is important for substrate affinity and catalytic activity because it determinates H-loop conformation <ref>Huanchen Wang, Yudong Liu, Qing Huai, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Jackie D. Corbin, Howard Robinson, Zhongcheng Xin, Guiting Lin, and Hengming Ke Zhongcheng Xin, Guiting Lin and Hengming Jackie D. Corbin, Howard Robinson, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Huanchen Wang, Yudong Liu, Qing Huai, Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development, The Journal of Biological Chemistry VOL. 281, NO. 30, pp. 21469–21479, July 28, 2006</ref> (see below).<br \> | ||
H-loop is important in the substrate recognition and the interactions with, it is <scene name='60/604476/H_loop/1'>from 660th to 693th residues</scene>. H-loop has the same interactions with cGMP and Sildenafil (cf. Inhibitor) because it's related to its role of substrate binding | H-loop is important in the substrate recognition and the interactions with, it is <scene name='60/604476/H_loop/1'>from 660th to 693th residues</scene>. H-loop has the same interactions with cGMP and Sildenafil (cf. Inhibitor) because it's related to its role of substrate binding<ref>Huanchen Wang, Yudong Liu, Qing Huai, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Jackie D. Corbin, Howard Robinson, Zhongcheng Xin, Guiting Lin, and Hengming Ke Zhongcheng Xin, Guiting Lin and Hengming Jackie D. Corbin, Howard Robinson, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Huanchen Wang, Yudong Liu, Qing Huai, Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development, The Journal of Biological Chemistry VOL. 281, NO. 30, pp. 21469–21479, July 28, 2006</ref>. But The H-loop is not well understood, because when it's modified, the enzyme's function is practically not modified.<ref>Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H. Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281: 21469–21479, 2006.</ref> But it also may have a role for inhibitor fixation.<br \> | ||
Nowadays catalysis mechanism is not well know: there could be a, nucleophile attack of a water molecule on the substrate | Nowadays catalysis mechanism is not well know: there could be a, nucleophile attack of a water molecule on the substrate <ref>Sharron H. Francis, Mitsi A. Blount, And Jackie D. Corbin, Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions, Physiol Rev 91:651-690, 2011. doi:10.1152/physrev.00030.2010</ref>. | ||
== Inhibition == | == Inhibition == | ||
In the treatment erection dysfunction, the inhibitors Sildenafil, Vardenafil and Tadalafil are used, like in the pulmonary hypertension | In the treatment erection dysfunction, the inhibitors Sildenafil, Vardenafil and Tadalafil are used, like in the pulmonary hypertension<ref>Sharron H. Francis, Mitsi A. Blount, And Jackie D. Corbin, Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions, Physiol Rev 91:651-690, 2011. doi:10.1152/physrev.00030.2010</ref>. Sildenafil may cure sleeping trouble after a intercontinental travel <ref>Agostino PV, Plano SA, Golombek DA. Sildenafil accelerates reentrainment of circadian rhythms after advancing light schedules. Proc Natl Acad Sci USA 104: 9834–9839, 2007.</ref>, may help to recover neural liaisons after an injury (the motor function<ref>Zhang L, Zhang RL, Wang Y, Zhang C, Zhang ZG, Meng H, Chopp M. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 36: 847–852, 2005.<br \> | ||
Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, Chopp M. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res 1118: 192–198, 2006.<br \> | |||
Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, Zhang L, Chopp M. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33: 2675–2680, 2002.<br \> | |||
Zhang RL, Zhang Z, Zhang L, Wang Y, Zhang C, Chopp M. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 83: 1213–1219, 2006.</ref> and the sensory motor function<ref>Menniti FS, Ren J, Coskran TM, Liu J, Morton D, Sietsma DK, Som A, Stephenson DT, Tate BA, Finklestein SP. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. J Pharmacol Exp Ther 331: 842–850, 2009.</ref>) and can be vascular effects.<br \> | |||
<gallery>Image:Sildenafil.jpg|500px|Sildenafil Inhibitor, R1 in blue, R2 in green and R3 in red | |||
Image:Sildenafilspace.jpg|500px|Sildenafil Inhibitor in the space in the enzyme</gallery> | |||
* PDE5 inhibitors might help physical condition in Duchene muscular dystrophy | * PDE5 inhibitors might help physical condition in Duchene muscular dystrophy<ref>Asai A, Sahani N, Kaneki M, Ouchi Y, Martyn JA, Yasuhara SE. Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS One 2: e806, 2007. | ||
Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, Parikh SV, Weiss RM, Chamberlain JS, Moore SA, Campbell KP. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456: 511–515, 2008.</ref>, improve of cognitive function <ref>Verhoest PR, Proulx-Lafrance C, Corman M, Chenard L, Helal CJ, Hou X, Kleiman R, Liu S, Marr E, Menniti FS, Schmidt CJ, Vanase-Frawley M, Schmidt AW, Williams RD, Nelson FR, Fonseca KR, Liras S. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. J Med Chem 52: 7946–7949, 2009. | |||
Rutten K, Van Donkelaar EL, Ferrington L, Blokland A, Bollen E, Steinbusch HW, Kelly PA, Prickaerts JH. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. Neuropsychopharmacology 34: 1914–1925, 2009 | |||
Rutten K, Vente JD, Sik A, Ittersum MM, Prickaerts J, Blokland A. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav Brain Res 164: 11–16, 2005. | |||
Schmidt CJ. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr Top Med Chem 10: 222–230, 2010. | |||
Walter U, Gambaryan S. cGMP and cGMP-dependent protein kinase in platelets and blood cells. Handb Exp Pharmacol 533–548, 2009.</ref>and have antidepressant effect<ref>Liebenberg N, Harvey BH, Brand L, Brink CB. Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. Behav Pharmacol 21: 540–547, 2010.</ref> , also they might have an artero<ref>Kemp-Harper B, Schmidt HH. cGMP in the vasculature. Handb Exp Pharmacol 447–467, 2009.</ref> and endothelial cell protective effect<ref>Aversa A, Bruzziches R, Vitale C, Marazzi G, Francomano D, Barbaro G, Spera G, Rosano GM. Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opin Drug Metab Toxicol 3: 451–464, 2007. | |||
Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47: 214–220, 2005.</ref> so they have cardiac protection effect<ref>Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res 57: 22–27, 2005. | |||
Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase- 5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111: 1601–1610, 2005. | |||
Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, Fisher PW, Wittkamp M, Hawkins J, Chou E, Kukreja AK, Wang X, Marwaha VR, Xi L. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol 42: 219–232, 2005. | |||
Sahara M, Sata M, Morita T, Nakajima T, Hirata Y, Nagai R. A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis | |||
through a protein kinase G-dependent hypoxia-inducible factor-1/ vascular endothelial growth factor pathway. Arterioscler Thromb Vasc Biol 30: 1315–1324, 2010. | |||
Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294: H1398–H1406, 2008. | |||
Salloum FN, Chau VQ, Hoke NN, Abbate A, Varma A, Ockaili RA, Toldo S, Kukreja RC. Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein- kinase g-dependent generation of hydrogen sulfide. Circulation 120: S31–S36, 2009. | |||
Salloum FN, Ockaili RA, Wittkamp M, Marwaha VR, Kukreja RC. Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol 40: 405–411, 2006. | |||
Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214–222, 2005.</ref> (controversial, cf. clinical trial “RELAX”), finally they slow tumer cell growth (Tadalafil-like)<ref>Abadi AH, Abouel-Ella DA, Ahmed NS, Gary BD, Thaiparambil JT, Tinsley HN, Keeton AB, Piazza GA. Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. Arzneimittelforschung 59: 415– 421, 2009</ref><br \> | |||
* There are other PDE5 inhibitors: IBMX, Icarisid II and Udenafil.<br \> | * There are other PDE5 inhibitors: IBMX, Icarisid II and Udenafil.<br \> | ||
* No interaction between the M site and the inhibitors<br \> | * No interaction between the M site and the inhibitors<br \> | ||
Line 54: | Line 77: | ||
Binding amino acid for the Sildenafil:<br \> | Binding amino acid for the Sildenafil:<br \> | ||
* R1 group have contacts with <scene name='60/604476/R1-1/1'>Gln817</scene> (2 hydrogen bounds, so it increases Sildenafil affinity), <scene name='60/604476/R1-1/1'>Phe820</scene> (Sildenafil stacks against it), <scene name='60/604476/R1-1/1'>Try612</scene> (hydrogen bound so it increases Sildenafil affinity | * R1 group have contacts with <scene name='60/604476/R1-1/1'>Gln817</scene> (2 hydrogen bounds, so it increases Sildenafil affinity), <scene name='60/604476/R1-1/1'>Phe820</scene> (Sildenafil stacks against it), <scene name='60/604476/R1-1/1'>Try612</scene> (hydrogen bound so it increases Sildenafil affinity <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref>), <scene name='60/604476/R1-1/1'>Leu765</scene> and <scene name='60/604476/R1-1/1'>Ala767</scene> <ref>Huanchen Wang, Yudong Liu, Qing Huai, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Jackie D. Corbin, Howard Robinson, Zhongcheng Xin, Guiting Lin, and Hengming Ke Zhongcheng Xin, Guiting Lin and Hengming Jackie D. Corbin, Howard Robinson, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Huanchen Wang, Yudong Liu, Qing Huai, Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development, The Journal of Biological Chemistry VOL. 281, NO. 30, pp. 21469–21479, July 28, 2006</ref>. And there is hydrophobic interactions between the pyrazol ring and residues <scene name='60/604476/R1-2/1'>Val782, Leu785, Tyr612 and Phe820</scene> <ref>Byung-Je Sung, Kwang Yeon Hwang, Young Ho Jeon, Jae Il Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro & Joong Myung Cho, Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules, NATURE, VOL 425, 4 SEPTEMBER 2003</ref>.<br \> | ||
* R2 group is in the H pocket and has Van der Waals bounds with Val 782, Ala 783, Phe 786, Leu 804, Ile 813, Gln 817, Phe801. And interaction Pi-Pi between the phenyl ring and the Phe820.<br \> | * R2 group is in the H pocket and has Van der Waals bounds with Val 782, Ala 783, Phe 786, Leu 804, Ile 813, Gln 817, Phe801. And interaction Pi-Pi between the phenyl ring and the Phe820.<br \> | ||
* R3 group is in the L pocket and has contacts with Asn 662, Ser 663, Tyr 664, Ile 665 (in the H-loop), Leu 804, Phe 801 | * R3 group is in the L pocket and has contacts with <scene name='60/604476/662_804/1'>Asn 662, Ser 663, Tyr 664, Ile 665 (in the H-loop), Leu 804, Phe 801</scene> | ||
* Gly659 is modified by Sildenafil presence in PDE5, ϕ and φ angles are increased (from 76-105° to 104-109° for ϕ and from 3-22° to 139-141° for φ) and ω angle is not changed. | * <scene name='60/604476/Gly659/2'>Gly659</scene> is modified by Sildenafil presence in PDE5, ϕ and φ angles are increased (from 76-105° to 104-109° for ϕ and from 3-22° to 139-141° for φ) and ω angle is not changed. <ref>Huanchen Wang, Yudong Liu, Qing Huai, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Jackie D. Corbin, Howard Robinson, Zhongcheng Xin, Guiting Lin, and Hengming Ke Zhongcheng Xin, Guiting Lin and Hengming Jackie D. Corbin, Howard Robinson, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Huanchen Wang, Yudong Liu, Qing Huai, Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development, The Journal of Biological Chemistry VOL. 281, NO. 30, pp. 21469–21479, July 28, 2006</ref><br \> | ||
H-loop:<br \> | H-loop:<br \> | ||
For each inhibitor, H-loop take a different and originally (comparatively to other PDEs) tertiary structure (and there are also minor modifications of the N-loop (788-811) ):<br \> | For each inhibitor, <scene name='60/604476/H_loop/1'>H-loop</scene> take a different and originally (comparatively to other PDEs) tertiary structure (and there are also minor modifications of <scene name='60/604476/N_loop/1'>the N-loop (788-811)</scene> ):<br \> | ||
* For an unliganded PDE5, H-loop take a coil conformation. | * For an unliganded PDE5, <scene name='60/604476/H_loop/1'>H-loop</scene> take a coil conformation. <ref>Huanchen Wang, Yudong Liu, Qing Huai, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Jackie D. Corbin, Howard Robinson, Zhongcheng Xin, Guiting Lin, and Hengming Ke Zhongcheng Xin, Guiting Lin and Hengming Jackie D. Corbin, Howard Robinson, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Huanchen Wang, Yudong Liu, Qing Huai, Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development, The Journal of Biological Chemistry VOL. 281, NO. 30, pp. 21469–21479, July 28, 2006</ref><br \> | ||
* In case of Sildenafil binding, a turn and an | * In case of Sildenafil binding, a turn and an 3ind10<scene name='60/604476/3-10helix/1'> helix (from 672 to 675)</scene> appear, and <scene name='60/604476/668_676/1'>from 668 to 676</scene> The all loop cover the active site (by migrate of 24 Å from unliganded PDE5 loop structure, so the active site become a closed pocket). <ref>Huanchen Wang, Yudong Liu, Qing Huai, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Jackie D. Corbin, Howard Robinson, Zhongcheng Xin, Guiting Lin, and Hengming Ke Zhongcheng Xin, Guiting Lin and Hengming Jackie D. Corbin, Howard Robinson, Jiwen Cai, Roya Zoraghi, Sharron H. Francis, Huanchen Wang, Yudong Liu, Qing Huai, Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development, The Journal of Biological Chemistry VOL. 281, NO. 30, pp. 21469–21479, July 28, 2006</ref><br \> | ||
* H-loop is less important in the interactions for Sildenafil and Icarisid II than cGMP.<br \> | * H-loop is less important in the interactions for Sildenafil and Icarisid II than cGMP.<br \> | ||
== Regulation == | == Regulation == | ||
As it is written over, there are 2 regulatory domains (GAF A and GAF B). In cGMP pathway, PDE5 allows a negative feedback of the molecule: first, in presence of cGMP, it binds GAF A which stimulates the catalysis in the active site, and vice versa. Moreover, cGMP actives PKG which phophorylates PDE5, that is stimulated by the presence of cGMP on the GAF A or/and the active site. If the protein is not binding with cGMP but it is phophorylated, that stimulates the binding of cGMP on GAF A and the catalytic site. So cGMP presence overstimulates the catalysis | As it is written over, there are 2 regulatory domains (GAF A and GAF B). In cGMP pathway, PDE5 allows a negative feedback of the molecule: first, in presence of cGMP, it binds GAF A which stimulates the catalysis in the active site, and vice versa. Moreover, cGMP actives PKG which phophorylates PDE5, that is stimulated by the presence of cGMP on the GAF A or/and the active site. If the protein is not binding with cGMP but it is phophorylated, that stimulates the binding of cGMP on GAF A and the catalytic site. So cGMP presence overstimulates the catalysis <ref>Okada D, Asakawa S. Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP. Biochemistry 41: 9672–9679, 2002 | ||
Weber G. Energetics of ligand binding to protein. Adv Protein Chem 29: 1–83, 1975. | |||
Bessay EP, Blount MA, Zoraghi R, Beasley A, Grimes KA, Francis SH, Corbin JD. Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. J Pharmacol Exp Ther 325: 62–68, 2008.</ref>. And it also increase inhibitor's affinity<ref>Bessay EP, Zoraghi R, Blount MA, Grimes KA, Beasley A, Francis SH, Corbin JD. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Front Biosci 12: 1899–1910, 2007.</ref> and without cGMP, inhibitor don’t bind the PDE5 <ref>JD Corbin, Mechanisms of action of PDE5 inhibition in erectile dysfunction, International Journal of Impotence Research (2004) 16, S4–S7</ref>.<br \> | |||
== The NO Pathway == | == The NO Pathway == | ||
In the penile erection example, the nervous cell and/or epithelial cells are produced Nitrogen Oxide (NO) by the NOS (NO synthetase) from L-arginine and O2. They release NO in the extracellular environment going into vascular smooth cells and binding the Guanylyl Cyclase. This enzyme synthesizes cGMP from GMP, which stimulates the PKG. Finally, the calcium level is lower and the muscle cell relaxes and the Corpus Cavernosum rigidity increases. The PDE5 regulates the cGMP level making a negative feedback and can stop the rigidity. | In the penile erection example, the nervous cell and/or epithelial cells are produced Nitrogen Oxide (NO) by the NOS (NO synthetase) from L-arginine and O2. They release NO in the extracellular environment going into vascular smooth cells and binding the Guanylyl Cyclase. This enzyme synthesizes cGMP from GMP, which stimulates the PKG. Finally, the calcium level is lower and the muscle cell relaxes and the Corpus Cavernosum rigidity increases. The PDE5 regulates the cGMP level making a negative feedback and can stop the rigidity. <ref>JD Corbin, Mechanisms of action of PDE5 inhibition in erectile dysfunction, International Journal of Impotence Research (2004) 16, S4–S7</ref><br \> | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |